The Prognostic Value of the Serum Iron, Ferritin, Hepcidin and CRP in Pretransplant Multiple Myeloma Patients | ||
| Aswan University Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 18 February 2025 | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/aumj.2025.342617.1169 | ||
| Authors | ||
| Barsina Adel Narooz* 1; Emad Farah Kholef2; omar El Henawy3 | ||
| 1Clinical pathology , faculty of medicine, Aswan University | ||
| 2Aswan University hospital | ||
| 31 Clinical Pathology Department, Faculty of Medicine, Aswan University, Aswan, Egypt. | ||
| Abstract | ||
| Multiple myeloma (MM) is a neoplasm of the hematopoietic system, classified by the World Health Organization (WHO) as a plasma cell neoplasm (Multiple MyelomaIt`s known that The annual worldwide incidence of multiple myeloma is about 6 -7 / 100,000 and forms 1% of all cancer. With the evolution of hematopoietic stem cell transplantation (HSCT) and the usage of new drugs such as proteasome inhibitors, immunomodulators, monoclonal antibodies, and immune checkpoint inhibitors, the overall survival (OS) of MM has been considerably improved Hepcidin, was first identified in human blood and urine as an antimicrobial small peptide, is now dellibrated to be a central molecule that regulates iron metabolism. Hepcidin decreases iron absorption from the intestine and blocks its release from iron stores by downregulating the expression of the cellular iron exporter ferroprotein. Hepatic expression of hepcidin can be upregulated by iron loading as well as by inflammatory stimuli such as interleukin-6 (IL-6). | ||
| Keywords | ||
| Multiple myeloma; Interleukin-6; Hepcidin; Hematopoietic Stem Cell Transplantation | ||
|
Statistics Article View: 63 |
||
